Literature DB >> 6192439

Primary structures of human alpha-fetoprotein and its mRNA.

T Morinaga, M Sakai, T G Wegmann, T Tamaoki.   

Abstract

DNA complementary to human alpha-fetoprotein (AFP)mRNA was cloned in the plasmid pBR322. Analysis of three overlapping cDNA clones revealed most of the nucleotide sequence of AFP mRNA, and the remaining nucleotides at the 5' end of the mRNA were elucidated from a cloned genomic DNA fragment. The amino acid sequence was deduced from the nucleotide sequence, which revealed 19 amino acids in the signal sequence and 590 amino acids in mature AFP. There are 15 regularly spaced disulfide bridges, which generate a folding structure having three repeating domains. There is one potential N-glycosylation site, Asn-Phe-Thr, in the amino acid sequence. In comparison with mouse AFP, 66% of the amino acid sequence was conserved, with the highest identity (72%) in domain 3, followed by domain 2 (67%) and domain 1 (59%). In comparison with human albumin, a 39% conservation of primary structure was found. Again, the similarity was the highest in domain 3 and the lowest in domain 1. Human AFP and human albumin are similar in overall structure, but certain parts of the molecules differ significantly in their predicted secondary structure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6192439      PMCID: PMC384092          DOI: 10.1073/pnas.80.15.4604

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Comparative study on the binding of estrogens by human and rat serum proteins in development.

Authors:  E Nunez; G Vallette; C Benassayag; M F Jayle
Journal:  Biochem Biophys Res Commun       Date:  1974-03-15       Impact factor: 3.575

2.  Preparation of antisera to alpha-fetoprotein making use of estradiol affinity column.

Authors:  R Arnon; E Teicher; M Bustin; M Sela
Journal:  FEBS Lett       Date:  1973-06-01       Impact factor: 4.124

3.  Estrogen-binding properties of rat, mouse and man fetospecific serum proteins. Demonstration by immuno-autoradiographic methods.

Authors:  J Uriel; B de Nechaud; M Dupiers
Journal:  Biochem Biophys Res Commun       Date:  1972-02-16       Impact factor: 3.575

4.  Alpha fetoprotein: structure and expression in man and inbred mouse strains under normal conditions and liver injury.

Authors:  E Ruoslahti; H Pihko; A Vaheri; M Seppälä; M Virolainen; A Konttinen
Journal:  Johns Hopkins Med J Suppl       Date:  1974

5.  Alpha-fetoprotein: immunochemical purification and chemical properties. Expression in normal state and in malignant and non-malignant liver disease.

Authors:  E Ruoslahti; H Pihko; M Seppälä
Journal:  Transplant Rev       Date:  1974

6.  Alpha-fetoprotein as a marker of embryo-specific differentiations in normal and tumor tissues.

Authors:  G I Abelev
Journal:  Transplant Rev       Date:  1974

Review 7.  Alpha-fetoprotein in ontogenesis and its association with malignant tumors.

Authors:  G I Abelev
Journal:  Adv Cancer Res       Date:  1971       Impact factor: 6.242

Review 8.  Glycoproteins.

Authors:  R G Spiro
Journal:  Adv Protein Chem       Date:  1973

9.  Prenatal stilbestrol experience of mothers of young cancer patients.

Authors:  P Greenwald; P C Nasca; W S Burnett; A Polan
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

10.  Isolation and characterization of a human fetal-alpha-globulin from the sera of fetuses and a hepatoma patient.

Authors:  S Nishi
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

View more
  47 in total

1.  Growth inhibition of human liver cancer cells by alpha-fetoprotein antisense strategy.

Authors:  X W Wang; H Xie
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-03       Impact factor: 2.416

2.  Detection of hepatoma cells in peripheral blood of HCC patients by nested RT-PCR.

Authors:  Yu-Hui Liu; Rou-Li Zhou; Jing-An Rui
Journal:  World J Gastroenterol       Date:  1998-04       Impact factor: 5.742

3.  Detection of blood AFPmRNA in nude mice bearing human HCC using nested RT-PCR and its significance.

Authors:  Yang Liu; Bai-He Zhang; Guang-Xiang Qian; Han Chen; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

4.  Low alpha-fetoprotein and serum albumin levels in Morbus Down may point to a common regulatory mechanism.

Authors:  T Voigtländer; F Vogel
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

5.  RFLPs for the human alphafetoprotein (AFP), at 4q11-4q13.

Authors:  J C Murray; K Watanabe; T Tamaoki; S Hornung; A Motulsky
Journal:  Nucleic Acids Res       Date:  1985-09-25       Impact factor: 16.971

6.  Evolutionary and structural relationships among the group-specific component, albumin and alpha-fetoprotein.

Authors:  F Yang; V J Luna; R D McAnelly; K H Naberhaus; R L Cupples; B H Bowman
Journal:  Nucleic Acids Res       Date:  1985-11-25       Impact factor: 16.971

7.  Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice.

Authors:  X W Wang; J H Yuan; R G Zhang; L X Guo; Y Xie; H Xie
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

8.  Expression of alpha fetoprotein messenger RNA in BEL-7404 human hepatoma cells and effect of L-4 oxalysine on the expression.

Authors:  Xing-Wang Wang; Bin Xu
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

9.  Lectin affinity electrophoresis in a yolk sac tumour in the vagina with yolk sac tumour-type glycoform of alpha fetoprotein.

Authors:  R Yamamoto; K Taketa; Y Ebina; Y Cho; H Hareyama; N Sakuragi; S Makinoda; K Kobayashi; S Nishi; S Fujimoto
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

10.  Circulating intercellular adhesion molecule 1 predicts non-specific elevation of alpha 1-fetoprotein.

Authors:  E Falleti; C Fabris; M Pirisi; G Soardo; D Vitulli; P Toniutto; E Bartoli; N Bortolotti; F Gonano
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.